论文部分内容阅读
本文作者为了查明小脑萎缩(Cerebellar attophy CA)是否会影响大剂量CBZ单一疗法病人的耐受性,对42例病人进行了对比研究。 全组患者均有复杂局部发作性癫痫,伴或不伴继发性全身性强直—阵挛发作,除外了突出为全身强直性发作和EEG显示双侧棘波发放的患者。 方法:单用CBZ疗法:每2～5天增加150～200mg。当出现一个典型体征(如眼球震颤、共济失调),或至少有两个典型症状(如头晕、复视)1小时内采集血样,使用HPLC法测量CBZ血清浓度及其代谢产物CBZ—10,11—环氧化物(CBZ—E)。全组病人均采用同一CT扫描,为排除幕下间隙大小和切面厚度等因素的估价影响,特选择了一个直
In order to determine whether cerebellar atopic CA affects the tolerability of high-dose CBZ monotherapy patients, we compared 42 patients. All patients had complicated partial-onset epilepsy with or without secondary generalized tonic-clonic severing, with the exception of those patients who had a tonic-normalized episode and a bilateral EEG-spike dissemination. Methods: CBZ therapy alone: every 2 to 5 days increased by 150 ~ 200mg. Blood samples were collected within 1 hour of typical signs such as nystagmus, ataxia, or at least two typical symptoms such as dizziness and diplopia. Serum concentrations of CBZ and its metabolites, CBZ-10, were measured by HPLC. 11-epoxide (CBZ-E). All patients were using the same CT scan, in order to exclude the screen under the gap size and thickness of the factors such as the valuation of the impact, select a straight